Aranoza in the Treatment of Metastatic Neuroendocrine Tumors (NETs): Single Institution Experience

#1275

Introduction: Aranoza (3-α-L-arabinopyranosyl-1-methyl-nitrosourea) – nitrosourea derivative, as STZ.

Aim(s): To evaluate the efficacy and safety of Aranoza in metastatic WD NETs

Materials and methods: We performed a prospective analysis of all pts treated with Aranoza (500 mg/m2 for 3 days every 3 weeks) at our center between July 2007 and July 2014. The median progression-free survival was calculated using Kaplan-Meier method. Treatment efficacy was evaluated according to RECIST

Conference: 13th Annual ENETSConcerence (2016)

Presenting Author:

Authors: Gorbunova V, Orel N, Kuzminov A, Emelianova G, Odintsova A,

Keywords: aranoza, Neuroendocrine tumors, chemotherapy,